Saltar al contenido
Merck

Genotype-based dosage of acenocoumarol in highly-sensitive geriatric patients.

International journal of clinical pharmacology and therapeutics (2015-02-12)
Roberto Lozano, María-Esther Franco, Luis López, Juan-José Moneva, Vicente Carrasco, Maria-Angeles Pérez-Layo
RESUMEN

Our aim was to determinate the acenocoumarol dose requirement in highly sensitive geriatric patients, based on a minimum of genotype (VKORC1 and CYP2C9) data. We used a Gaussian kernel density estimation test to identify patients highly sensitive to the drug and PHARMACHIP®-Cuma test (Progenika Biopharma, SA, Grifols, Spain) to determine the CYP2C9 and VKORC1 genotype. All highly sensitive geriatric patients were taking ≤5.6 mg/week of acenocoumarol (AC), and 86% of these patients presented the following genotypes: CYP2C9*1/*3 or CYP2C9*1/*2 plus VKORC1 A/G, CYP2C9*3/*3, or VKORC1 A/A. VKORC1 A and CYP2C9*2 and/or *3 allelic variants extremely influence on AC dose requirement of highly sensitive geriatric patients. These patients display acenocoumarol dose requirement of ≤5.6 mg/week.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
Ramipril, ≥98% (HPLC)
Número de referencia del producto (SKU)
Tamaño de envase
Disponibilidad
Precio
Cantidad
Supelco
Ramipril, Pharmaceutical Secondary Standard; Certified Reference Material
Número de referencia del producto (SKU)
Tamaño de envase
Disponibilidad
Precio
Cantidad
Ramipril, European Pharmacopoeia (EP) Reference Standard
Número de referencia del producto (SKU)
Tamaño de envase
Disponibilidad
Precio
Cantidad